Helus Pharma Prices $50 Mln Share Offering; Stock Up In Pre-market

Cybin D/B/A Helus Pharma priced an underwritten offering of about 10.3 million common shares at $4.85 each, raising $50 million in gross proceeds. The deal increases equity dilution for existing holders, though it bolsters the company’s cash resources. The announcement is routine financing news and is likely to have only a modest stock-specific impact.

Analysis

Cybin D/B/A Helus Pharma priced an underwritten offering of about 10.3 million common shares at $4.85 each, raising $50 million in gross proceeds. The deal increases equity dilution for existing holders, though it bolsters the company’s cash resources. The announcement is routine financing news and is likely to have only a modest stock-specific impact.